Merijn Constantijn Reuland

Dr. Merijn Constantijn Reuland

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2025 in Critical Care Medicine
Verified
Journal Article
Open access
SWStefan Franciscus van Wonderen
Stefan Franciscus van Wonderen
SRSenta Jorinde Raasveld
Senta Jorinde Raasveld
AFAndrew W J Flint
Andrew W J Flint
JSJimmy Schenk
Jimmy Schenk
COClaudia van Den Oord
Claudia van Den Oord
IGInPUT Study Group
InPUT Study Group
Objective: There is a lack of comprehensive international data regarding platelet transfusion practices in the ICU. This study aimed to evaluate the current occurrence rate of platelet transfusion in the ICU and provide an overview of platelet transfusion practices including indications for a platelet transfusion, thresholds, (non-)adherence and geo-economic region variations. Design: International prospective cohort study. Setting: Two hundred thirty-three centers in 30 countries worldwide. Patients: All patients 18 years old and older, admitted to the ICU during a single study week, selected by each site from one of the 16 predefined weeks (March 2019 to October 2022), were included. Interventions: None. Measurements and Main Results: Of the 3643 patients, 208 (6%) received a platelet transfusion during their ICU stay and main indications consisted of active bleeding (42%, n = 187/443), prophylaxis (33%, n = 144/443) or an upcoming procedure (12%, n = 51/443). The median platelet count before transfusion was 44 × 10 9 /L (interquartile range [IQR], 20–78) with variation by indication, including a higher median of 60 × 10 9 /L (IQR 31–93) during active bleeding. A threshold for transfusion was stated in 51% ( n = 224/443) of the events, with a median threshold platelet count of 50 × 10 9 /L (IQR, 40–100). The advised threshold was not adhered to in 16% ( n = 36/224) of cases, with the majority having active bleeding as indication. Contrasts in transfusion practices were observed across different geo-economic regions. Platelet transfusions were administered to 6% ( n = 156/2520) of patients in high-income countries, 5% ( n = 52/1069) of patients in upper-middle-income countries and in none from lower-middle-income countries ( n = 0/54). Non-adherence was higher in the high-income countries (23%, n = 34/149) than upper-middle-income countries (3%, n = 2/75). Conclusions: Platelet transfusions were administered to a small proportion of critically ill patients, and were given to treat active bleeding or as prophylaxis in the majority of cases. Occurence rate, indication and threshold adherence for platelet transfusion widely varied between geo-economic regions.

18 December 2024 in Transfusion
Verified
Journal Article
Open access
MHMaite M. T. van Haeren
Maite M. T. van Haeren
SRSenta Jorinde Raasveld
Senta Jorinde Raasveld
SBSanne de Bruin
Sanne de Bruin
MRMerijn Constantijn Reuland
Merijn Constantijn Reuland
COClaudia van Den Oord
Claudia van Den Oord
TGthe InPUT Study Group
the InPUT Study Group
Background: Current guidelines discourage prophylactic plasma use in non‐bleeding patients. This study assesses global plasma transfusion practices in the intensive care unit (ICU) and their alignment with current guidelines.Study Design and Methods: This was a sub‐study of an international, prospective, observational cohort. Primary outcomes were in‐ICU occurrence rate of plasma transfusion, proportion of plasma events of total blood products events, and number of plasma units per event. Secondary outcomes included transfusion indications, INR/PT, and proportion of events for non‐bleeding indications.Results: Of 3643 patients included, 356 patients (10%) experienced 547 plasma transfusion events, accounting for 18% of total transfusion events. A median of 2 (IQR 1, 2) units was given per event excluding massive transfusion protocol (MTP) and 3 (IQR 2, 6) when MTP was activated. MTP accounted for 39 (7%) of events. Indications of non‐MTP events included active bleeding (54%), prophylactic (25%), and pre‐procedure (12%). Target INR/PT was stated for 43% of transfusion events; pre‐transfusion INR/PT or visco‐elastic hemostatic assays (VHA) were reported for 73%. Thirty‐seven percent of events were administered for non‐bleeding indications, 54% with a pre‐transfusion INR < 3.0 and 30% with an INR < 1.5.Discussion: Plasma transfusions occurred in 10% of ICU patients. Over a third were given for non‐bleeding indications and might have been avoidable. Target INR/PT was not stated in more than half of transfusions, and pre‐transfusion INR/PT or VHA was not reported for 27%. Further research and education is needed to optimize guideline implementation and to identify appropriate indications for plasma transfusion.

24 November 2025 in Critical Care
Verified
Journal Article
Open access
PDF file
MRMerijn Constantijn Reuland
Merijn Constantijn Reuland
SRSenta Jorinde Raasveld
Senta Jorinde Raasveld
DDDave A. Dongelmans
Dave A. Dongelmans
PEPaul W.G. Elbers
Paul W.G. Elbers
MMMarcella C. A. Müller
Marcella C. A. Müller
AVAlexander P. J. Vlaar
Alexander P. J. Vlaar

1 May 2025 in Transfusion Clinique et Biologique
Verified
Journal Article
Open access
MRMerijn Constantijn Reuland
Merijn Constantijn Reuland
SRSenta J. Raasveld
Senta J. Raasveld
AVAlexander P.J. Vlaar
Alexander P.J. Vlaar
MMMarcella C.A. Müller
Marcella C.A. Müller
The balance between the risks and benefits of red blood cell (RBC) transfusions in critically ill patients is of ongoing debate. Clinical guidelines suggest a restrictive transfusion strategy with a transfusion hemoglobin trigger of 7 g/dL for most critically ill patients. However, recent literature shows many RBC transfusions are given with a prior hemoglobin above 7 g/dL. We aimed to evaluate adherence to our own transfusion protocol and changes in transfusion policy over time for the entire Intensive Care Unit (ICU) and in subgroups. Retrospective observational cohort study of patients admitted between 2017 and 2024 to the ICU of Amsterdam UMC. Data was extracted from the electronic health record and the Dutch national quality registry (NICE). Subgroup analysis was done based on referring specialty. In total 24 761 ICU stays were analyzed with 12 064 RBC transfusions in 3444 ICU stays. Median hemoglobin value before RBC transfusion decreased from 7.7 g/dL (1st-3rd quartile 7.1 - 8.4) in 2017 to 6.8 g/dL ((1st-3rd quartile 6.4 - 7.3) in 2024 (p<0.001). This decrease was present in all subgroups. The percentage of RBC transfusions with a prior hemoglobin <7 g/dL increased from 18.8% to 64.8% (p<0.001). We report the long term successful implementation of a comprehensive restrictive RBC transfusion protocol in a tertiary care ICU, independent of the patient's referring specialty. A median hemoglobin level of 6.8 g/dL before RBC transfusion was reached in 2024.

24 November 2025 in Vox Sanguinis
Verified
Journal Article
Open access
CSCaroline M Schaap
Caroline M Schaap
LOLaurens A Oomen
Laurens A Oomen
SRSenta Jorinde Raasveld
Senta Jorinde Raasveld
JSJimmy Schenk
Jimmy Schenk
SBSanne de Bruin
Sanne de Bruin
IGInPUT Study Group
InPUT Study Group
Background and Objectives: The number of critically ill patients with haematological conditions is increasing, yet transfusion practices in this population remain poorly defined. This study aimed to compare transfusion strategies in critically ill patients with versus without haematological conditions. Study Design and Methods: This international, prospective observational substudy of the International Point Prevalence Study of Intensive Care Unit [ICU] Transfusion Practices (InPUT) evaluated transfusion use in ICU patients with and without haematological conditions, including benign or malignant diseases or a history of stem cell transplantation. Outcomes included use of red blood cells (RBCs), platelets, plasma, haemostatic interventions, transfusion indications and thresholds. Results: Of 3643 ICU patients, 131 (3.6%) had a haematological condition. These patients were more likely to receive RBC (odds ratio [OR] 1.58, 95% confidence interval [CI] 1.09–2.29) and platelet transfusions (OR 8.32, 95% CI 5.09–13.6), primarily due to low haemoglobin rather than physiological triggers. Platelet thresholds were lower (median 23 × 10 9 /L vs. 64 × 10 9 /L) compared to non‐haematology patients. Both platelet and plasma transfusions were more frequently administered prophylactically rather than for active bleeding. Haemostatic interventions were more often used in haematology patients, at higher doses and typically without viscoelastic testing. Transfused haematology patients had higher 28‐day mortality and longer ICU stays. Conclusion: ICU patients with haematological conditions receive transfusions differently, particularly regarding platelet and plasma use. These findings underscore the need for prospective studies to define optimal transfusion thresholds in this growing and vulnerable patient population, although the study's limited sample size and lack of diagnostic granularity may affect interpretation.

22 October 2025 in Transfusion
Verified
Journal Article
Open access
VKVincent C. Kurucz
Vincent C. Kurucz
AFAndrew W. J. Flint
Andrew W. J. Flint
APAlexis Poole
Alexis Poole
MRMerijn Constantijn Reuland
Merijn Constantijn Reuland
COClaudia van Den Oord
Claudia van Den Oord
SRSenta Jorinde Raasveld
Senta Jorinde Raasveld
Background: Transfusion practices among intensive care unit (ICU) patients with sepsis vary widely. While restrictive hemoglobin thresholds for red blood cell (RBC) transfusion are well studied, the indications and thresholds for platelet and plasma transfusions remain uncertain. Methods: We performed a sepsis‐specific sub‐analysis of the International Point Prevalence Study of Intensive Care Unit Transfusion Practices , a prospective, multicenter, observational study capturing all adult ICU admissions during four pre‐scheduled weeks between March 2019 and October 2022. Patients admitted with sepsis or septic shock, or who developed sepsis during their ICU stay, were included. We recorded demographics, daily laboratory values, and transfusion triggers. Primary endpoints were the proportions of patients receiving RBCs, platelets, or plasma; secondary endpoints were indications, pre‐transfusion thresholds, and blood loss. Results: Among 3643 screened patients, 799 (22%) fulfilled sepsis criteria; within this subgroup, 317 (40%) received at least one blood component. RBCs were transfused in 269 patients (34%), primarily to address anemia or hemodynamic instability, at a mean pre‐transfusion hemoglobin of 7.5 ± 1.4 g/dL, consistent with restrictive practice. Platelets were given to 78 patients (10%) for prophylaxis or active bleeding at a median count of 26 × 10 9 cells/L (interquartile range 16–51 × 10 9 cells/L). Plasma was administered to 108 patients (14%), half for bleeding control and half for non‐bleeding indications. Conclusions: This largest international snapshot of septic ICU transfusion practices confirms adherence to restrictive RBC thresholds but reveals substantial variability in platelet and plasma use. These findings underscore the need for targeted trials to refine transfusion guidelines in sepsis.